Hint mode is switched on Switch off
For swift navigation between sections

Moderna
LEI 549300EI6OKH5K5Q2G38

PDF download

Choose all Reset all
Download Cancel
Organization name
Moderna, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Awards

News

09/05/2026 Wells Fargo Upgrades Moderna (MRNA) on Strong Flu Vaccine Data
06/05/2026 Moderna: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits
01/05/2026 Moderna (NASDAQ: MRNA) Q1 2026 Earnings: Revenue Beat and Strategic Pipeline Expansion
04/03/2026 Moderna, Inc. (NASDAQ: MRNA) Overview: Settlement Impact and Financial Stability
03/03/2026 Moderna: Entry Into A Material Definitive Agreement
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300EI6OKH5K5Q2G38
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001682852
  • EIN
    81-3467528
Registration is required to get access.